MacroGenics Signs Another Lucrative DART Deal with Janssen For $75m Up Front
Janssen Biotech Inc. apparently likes what it's seen so far from the first bi-specific antibody that it licensed from MacroGenics Inc., because the Johnson & Johnson subsidiary obtained rights to a second asset from the Rockville, Maryland-based firm's Dual Affinity Re-Targeting (DART) platform.
You may also be interested in...
MacroGenics has regained global rights to one of its DART compounds from Takeda, following a reprioritization of therapeutic areas by the Japanese firm that may open up new partnering opportunities in autoimmune disorders.
MacroGenics Inc. will study the ability of margetuximab to enhance the immune system's destruction of HER2-positive tumors in a Phase Ib/II clinical trial to evaluate the monoclonal antibody in combination with Merck & Co.'s PD-1 inhibitor Keytruda (pembrolizumab) in advanced gastric cancer.
Janssen Biotech, a unit of Johnson and Johnson, has struck a licensing deal with clinical-stage biopharma MacroGenics for the development of the latter firm's CD19-directed therapy, MGD011.